Therefore, the activation of the FGFR is likely to be another cause of resistance to EGFR-TKIs, and the combination of FGFR-TKIs and EGFR-TKIs is effective in glioblastoma and non-small cell lung cancer, as previously reported [42,43]. Here, EGFR is linked to non-small cell lung carcinoma.